株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

院内細菌感染の世界市場:2017年までの見通し

Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma

発行 GBI Research 商品コード 227586
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
院内細菌感染の世界市場:2017年までの見通し Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma
出版日: 2011年12月31日 ページ情報: 英文 86 Pages
概要

当レポートでは、世界の院内細菌感染(HABI)市場に影響を及ぼす促進因子および抑制因子を分析するとともに、米国、欧州主要5ヶ国、日本の各市場について分析し、治療の利用パターン、売上、価格、2017年までの見通し、主要企業、M&Aなどについてまとめ、概略下記の構成で取り上げております。

第1章 目次

第2章 世界の院内細菌感染市場:イントロダクション

第3章 世界の院内細菌感染市場:市場概要

  • イントロダクション
  • 収益見通し
  • 市場促進因子
  • 市場抑制因子

第4章 世界の院内細菌感染市場:治療の状況

  • 院内尿路感染症(UTI)市場
  • 院内細菌性肺炎(HABP)市場
  • 院内細菌手術部位感染市場
  • 院内細菌血液感染(BSI)市場

第5章 世界の院内細菌感染市場:地域別の状況

  • 地域別
  • 米国
  • 欧州主要5ヶ国
  • 日本

第6章 世界の院内細菌感染市場:パイプライン分析

  • 開発段階別パイプライン薬
  • 研究開発パイプライン
  • 主な開発後期段階薬剤のプロファイル

第7章 世界の院内細菌感染市場:競合状況

  • 競合状況

第8章 世界の院内細菌感染市場:戦略的合併

  • 概要
  • 地域別M&A取引
  • 価格別M&A取引
  • 取引種別M&A取引
  • R&Dライセンス契約

第9章 世界の院内細菌感染市場:付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Summary

The global hospital acquired bacterial infections market mainly comprises of four indications which are Urinary Tract Infections (UTI), pneumonia, Bloodstream Infections (BSI) and Surgical Site Infections (SSI). The total market of HABI is dependent on the major infections which are mainly caused by multi-drug resistant bacteria. Increasing human resistance to anti-bacterials leads to a need for advanced therapies to treat bacterial infections. Patent expiry of major antibacterials like Zyvox, Invanz, Tobi and Levaquin is set to erode the HABI market. This decline in the market will not be corrected by new product launches of pipeline molecules. Pharmaceutical companies show less interest in antibacterial R&D due to low Return on Investment (RoI). The lifespan of antibacterials is frequently limited due to the development of drug resistance. Big Pharma prefers acquiring small and niche pharmaceutical companies to widen their antibacterial pipeline portfolio.

The HABI market will show decline in the forecast period. The market is forecast to decline at a negative CAGR of 3.4% in the forecast period 2010-2017. Decline in the HABI market will be due to two main reasons. Firstly, there is resistance developed against antibacterials which makes existing antibacterials obsolete in some conditions. Secondly, there is an increase in hospital surveillance which leads to a decline in HABIs. Based on CDC data, 20% to 30% of hospital acquired infections can be prevented by infection control programs. There is formation of government bodies which are making it mandatory for hospitals to cut down on the spread of infections in the healthcare setup.

Scope

  • Annualized market data for the HABI market from 2002 to 2010, forecast forward to 2017.
  • Analysis of the leading therapeutic segments, including UTI, Pneumonia, SSI and BSI.
  • Analysis of the HABI market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
  • Market characterization of the HABI market, including market size, annual cost of therapy and treatment usage patterns.
  • Key drivers and barriers that have a significant impact on the market.
  • Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, J&J, Cubist and other niche companies like Trius Therapeutics and Tetraphase Pharmaceuticals.
  • Key M&A activities, licensing agreements, that have taken place since 2004 in HABI market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies and niche companies which are helpful in extending pipeline portfolio.
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma”. It provides in-depth analysis of the drivers and barriers that affect the global Hospital Acquired Bacterial Infections (HABI) market. The report analyzes the markets for HABI in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales and prices are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Hospital Acquired Bacterial Infections (HABI) Market is Expected to Lose $422m Market Value Between 2010 and 2017

The HABI market grew at a Compound Annual Growth Rate (CAGR) of 1.8% from 2002 to 2010 and is forecast to decline at a negative CAGR of 3.7% from 2010 to 2017. The decline in the HABI market in the forecast period will be due to patent expiries of some of the major drugs which are used for hospital acquired bacterial infections and an increase in the hospital surveillance to keep a check on hospital acquired infections. This market nevertheless seems lucrative because premium pricing of novel antibacterials drugs can be achieved. Novel antibacterials will fill the need gap which is currently present in the HABI market. Immuno-compromised patients are more prone to get hospital acquired bacterial infections. It has been observed that patients in the Intensive Care Units (ICUs) get HABI more frequently than those patients who are in the non-ICU wards of the hospital.

Pharmaceutical Companies Prefer Acquisitions to Any Other Deal Type to Penetrate More into the HABI Market

Acquisitions accounted for 89.7% while mergers accounted for 10.3% of the total Merger and Acquisition (M&A) deals. This signifies that from 2004-2011, pharmaceutical companies expanded their presence in the HABI market primarily by acquisitions.

The value of deals is mainly in the range of less than $100m so it is inferred that deals with small and niche companies accounted for a major proportion of all deals that took place in the antibacterials market.

Pipeline for HABI is dominated by Phase II Molecules

The pipeline molecules for HABI are in different phases of development. Due to resistance developed against antibacterials, it is important for pharmaceutical companies to have a rich antibacterial pipeline portfolio. This is the reason why high revenues can be generated for a relatively short period of time from antibacterials.

The percentage of molecules in the Phase II of development accounts for 36% to the total molecules in the pipeline. Phase III molecules account for 22% to the total pipeline molecules in the pipeline for HABI.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Global Hospital Acquired Bacterial Infections Market - Introduction

  • 2.1 GBI Research Report Guidance

3. Global Hospital Acquired Bacterial Infections Market - Market Overview

  • 3.1 Introduction
  • 3.2 Revenue Forecasts for the Global Hospital Acquired Bacterial Infections Market
    • 3.2.1 Sales Value
    • 3.2.2 Annual Cost of Therapy
    • 3.2.3 Treatment Usage Patterns
  • 3.3 Hospital Acquired Bacterial Infections Market Drivers
    • 3.3.1 Increase in Antibacterial Resistance due to Their Frequent Usage
    • 3.3.2 Threat from Emergence of Superbugs
  • 3.4 Hospital Acquired Bacterial Infections Market Restraints
    • 3.4.1 Increased Penetration of Generics Pose as a Threat for Primary Manufacturers
    • 3.4.2 Increased Anti-bacterial Surveillance in Hospitals

4. Global Hospital Acquired Bacterial Infections Market - Therapeutic Landscape

  • 4.1 Hospital Acquired Urinary Tract Infections (UTI) Market
    • 4.1.1 Introduction
    • 4.1.2 Sales Value
    • 4.1.3 Annual Cost of Therapy
    • 4.1.4 Treatment Flow Algorithm
    • 4.1.5 Treatment Usage Patterns
    • 4.1.6 Market Share by Geography
  • 4.2 Hospital Acquired Bacterial Pneumonia (HABP) Market
    • 4.2.1 Introduction
    • 4.2.2 Sales Value
    • 4.2.3 Annual Cost of Therapy
    • 4.2.4 Treatment Flow Algorithm
    • 4.2.5 Treatment Usage Patterns
    • 4.2.6 Market Share by Geography
  • 4.3 Hospital Acquired Bacterial Surgical Site Infections Market
    • 4.3.1 Introduction
    • 4.3.2 Sales Value
    • 4.3.3 Annual Cost of Therapy
    • 4.3.4 Treatment Flow Algorithm
    • 4.3.5 Treatment Usage Patterns
    • 4.3.6 Market Share by Geography
  • 4.4 Hospital Acquired Bacterial Blood Stream Infections (BSI) Market
    • 4.4.1 Introduction
    • 4.4.2 Sales Value
    • 4.4.3 Annual Cost of Therapy
    • 4.4.4 Treatment Flow Algorithm
    • 4.4.5 Treatment Usage Patterns
    • 4.4.6 Market Share by Geography

5. Global Hospital Acquired Bacterial Infections Market - Geographical Landscape

  • 5.1 Geographical Break-up
  • 5.2 The US
    • 5.2.1 Sales Value
    • 5.2.2 Annual Cost of Therapy
    • 5.2.3 Treatment Usage Patterns
  • 5.3 Top Five Countries in Europe
    • 5.3.1 Sales Value
    • 5.3.2 Country Segmentation
    • 5.3.3 Annual Cost of Therapy
    • 5.3.4 Treatment Usage Patterns
  • 5.4 Japan
    • 5.4.1 Sales Value
    • 5.4.2 Annual Cost of Therapy
    • 5.4.3 Treatment Usage Patterns

6. Global Hospital Acquired Bacterial Infections - Pipeline Analysis

  • 6.1 Pipeline Drugs by Phase of Development
  • 6.2 Research and Development Pipeline
    • 6.2.1 Phase III Pipeline Molecules
    • 6.2.2 Phase II Pipeline Molecules
    • 6.2.3 Phase I, Pre-Clinical and Discovery Phase Molecules
  • 6.3 Profiles of Key Late Stage Drugs
    • 6.3.1 Oritavancin
    • 6.3.2 Torezolid
    • 6.3.3 Ceftobiprole Medocaril
    • 6.3.4 Omadacycline/ PTK 0796
    • 6.3.5 Oritavancin

7. Global Hospital Acquired Bacterial Infections Market - Competitive Landscape

  • 7.1 Competitive Profiling
    • 7.1.1 Johnson & Johnson (J&J)
    • 7.1.2 Pfizer
    • 7.1.3 Cubist Pharmaceuticals
    • 7.1.4 Bayer
    • 7.1.5 Trius Therapeutics
    • 7.1.6 Tetraphase Pharmaceuticals Inc.

8. Global Hospital Acquired Bacterial Infections Market - Strategic Consolidations

  • 8.1 Overview
  • 8.2 M&A Deals by Geography
  • 8.3 M&A Deals by Value
  • 8.4 M&A Deals by Deal Type
    • 8.4.1 Merck Completes Acquisition Of Inspire Pharmaceuticals
    • 8.4.2 SciClone Pharmaceuticals Acquires NovaMed Pharmaceuticals
    • 8.4.3 AstraZeneca Completed the Acquisition of Novexel SA in March 2010
  • 8.5 R&D Licensing Agreements
    • 8.5.1 Major Licensing Agreements

9. Global Hospital Acquired Bacterial Infections Market - Appendix

  • 9.1 Market Definitions
  • 9.2 Abbreviations
  • 9.3 Research Methodology
    • 9.3.1 Coverage
    • 9.3.2 Secondary Research
    • 9.3.3 Primary Research
    • 9.3.4 Therapeutic Landscape
    • 9.3.5 Market Size by Geography
    • 9.3.6 Geographical Landscape
    • 9.3.7 Pipeline Analysis
    • 9.3.8 Competitive Landscape
    • 9.3.9 Expert Panel Validation
  • 9.4 Contact Us
  • 9.5 Disclaimer
  • 9.6 Sources

List of Tables

  • Table 1: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2002-2010
  • Table 2: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2010-2017
  • Table 3: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 4: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 5: Hospital Acquired Bacterial Infections Market, Global, Treatment Usage Patterns (million), 2002-2010
  • Table 6: Hospital Acquired Bacterial Infections Market, Global, Treatment Usage Patterns (million), 2010-2017
  • Table 7: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2002-2010
  • Table 8: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2010-2017
  • Table 9: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 10: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 11: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2002-2010
  • Table 12: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2010-2017
  • Table 13: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2002-2010
  • Table 14: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2010-2017
  • Table 15: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2002-2010
  • Table 16: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2010-2017
  • Table 17: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 18: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 19: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2002-2010
  • Table 20: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2010-2017
  • Table 21: Hospital Acquired Bacterial Pneumonia Market, Global, Geographical Segmentation ($m), 2002-2010
  • Table 22: Hospital Acquired Bacterial Pneumonia Market, Global, Geographical Segmentation ($m), 2010-2017
  • Table 23: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2002-2010
  • Table 24: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2010-2017
  • Table 25: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 26: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 27: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (thousand), 2002-2010
  • Table 28: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (thousand), 2010-2017
  • Table 29: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2002-2010
  • Table 30: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2010-2017
  • Table 31: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2002-2010
  • Table 32: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2010-2017
  • Table 33: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 34: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 35: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (thousand), 2002-2010
  • Table 36: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (thousand), 2010-2017
  • Table 37: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2002-2010
  • Table 38: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2010-2017
  • Table 39: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2002-2010
  • Table 40: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2010-2017
  • Table 41: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2002-2010
  • Table 42: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2010-2017
  • Table 43: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2002-2010
  • Table 44: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2010-2017
  • Table 45: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2002-2010
  • Table 46: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2010-2017
  • Table 47: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2010
  • Table 48: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2010-2017
  • Table 49: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2010
  • Table 50: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2010-2017
  • Table 51: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010
  • Table 52: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017
  • Table 53: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Treatment Usage Pattern (thousand), 2002-2010
  • Table 54: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Treatment Usage Pattern (thousand), 2010-2017
  • Table 55: Hospital Acquired Bacterial Infections Market, Japan, Sales Value ($m), 2002-2010
  • Table 56: Hospital Acquired Bacterial Infections Market, Japan, Sales Value ($m), 2010-2017
  • Table 57: Hospital Acquired Bacterial Infections Market, Japan, Annual Cost of Therapy ($), 2002-2010
  • Table 58: Hospital Acquired Bacterial Infections Market, Japan, Annual Cost of Therapy ($), 2010-2017
  • Table 59: Hospital Acquired Bacterial Infections Market, Japan, Treatment Usage Pattern (thousand), 2002-2010
  • Table 60: Hospital Acquired Bacterial Infections Market, Japan, Treatment Usage Pattern (thousand), 2010-2017
  • Table 61: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase III, 2011
  • Table 62: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase II, 2011
  • Table 63: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase I, Discovery, Pre-Clinical, 2011
  • Table 64: Hospital Acquired Bacterial Infections Market, Global, Major M&A Deals, 2011

List of Figures

  • Figure 1: Hospital Acquired Bacterial Infections Market, Global, Drivers and Restraints, 2011
  • Figure 2: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2002-2017
  • Figure 3: Hospital Acquired Bacterial Infections Market, Global, Revenue Segmentation, 2010, 2017
  • Figure 4: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 5: Hospital Acquired Bacterial Infections Market, Global, Therapeutic Usage Patterns (million), 2002-2017
  • Figure 6: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2002-2017
  • Figure 7: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 8: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Flow Algorithm
  • Figure 9: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2002-2017
  • Figure 10: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2002-2017
  • Figure 11: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2002-2017
  • Figure 12: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 13: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Flow Algorithm
  • Figure 14: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2002-2017
  • Figure 15: Hospital Acquired Bacterial Pneumonia Market, Global, Market Geographical Segmentation ($m), 2002-2017
  • Figure 16: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2002-2017
  • Figure 17: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 18: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Flow Algorithm
  • Figure 19: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (million), 2002-2017
  • Figure 20: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2002-2017
  • Figure 21: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2002-2017
  • Figure 22: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 23: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Flow Algorithm
  • Figure 24: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (million), 2002-2017
  • Figure 25: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2002-2017
  • Figure 26: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2002-2017
  • Figure 27: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2002-2017
  • Figure 28: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2002-2017
  • Figure 29: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2002-2017
  • Figure 30: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2017
  • Figure 31: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2017
  • Figure 32: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017
  • Figure 33: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Treatment Usage Patterns (thousand), 2002-2017
  • Figure 34: Hospital Acquired Bacterial Infections Market, Japan, Sales Value ($m), 2002-2017
  • Figure 35: Hospital Acquired Bacterial Infections Market, Japan, Annual Cost of Therapy ($), 2002-2017
  • Figure 36: Hospital Acquired Bacterial Infections Market, Japan, Treatment Usage Pattern (thousand), 2002-2017
  • Figure 37: Hospital Acquired Bacterial Infections, Global, Pipeline by Phase (%), 2010
  • Figure 38: Hospital Acquired Bacterial Infections Market, Global, SWOT - Johnson & Johnson, 2010
  • Figure 39: Hospital Acquired Bacterial Infections Market, Global, SWOT - Pfizer, 2010
  • Figure 40: Hospital Acquired Bacterial Infections Market, Global, SWOT - Cubist, 2010
  • Figure 41: Hospital Acquired Bacterial Infections Market, Global, SWOT - Bayer, 2010
  • Figure 42: Hospital Acquired Bacterial Infections Market, Global, M&A Deals by Geography (%), 2004-2011
  • Figure 43: Hospital Acquired Bacterial Infections Market, Global, M&A Deals by Value (%), 2004-2011
  • Figure 44: Hospital Acquired Bacterial Infections Market, Global, Major M&A Deals by Deal Type (%), 2004-2011
  • Figure 45: Hospital Acquired Bacterial Infections Market, Global, Major Licensing Agreements By Geography (%), 2004-2011
  • Figure 46: Hospital Acquired Bacterial Infections Market, Global, Major Licensing Agreements By Value (%), 2004-2011
  • Figure 47: GBI Research Market Forecasting Model
Back to Top